Search Results for “EC” – Page 201 – media

As a new upstart in the imaging industry, is its billion-dollar halo no longer there?

Recently, United Imaging Healthcare released its 2024 semi-annual report. In the first half of the year, United Imaging Healthcare’s revenue was 5.333 billion yuan, a year-on-year increase of 1.18%; it achieved a net profit attributable to the parent of 950 million yuan, a year-on-year increase of 1.33%; and a net profit attributable to the parent of 798 million yuan, a year-on-year increase of 1.39%. In the semi-annual report, the growth of United Imaging Healthcare slowed down, and based on this, the stock price has been falling. Now that the market value of United Imaging Healthcare is not guaranteed, how can the upstart break through? Founded in 2011, United Imaging Healthcare is committed to providing global customers with a full range of independently developed high-performance medical imaging diagnostic and treatment equipment, life science instruments, and innovative solutions covering the entire chain of “basic research-clinical research-medical transformation”. Since its listing on the ...
- Source: drugdu
- 80
- September 6, 2024
Edge Medical Releases Remote Surgery System

The 18th Annual Meeting of Chinese Hospital Directors was grandly held in Wuhan, Hubei from August 30th to September 1st. During the grand event, Edge Medical® Heavy Release of Edge Cloud ® The remote surgery system has been fully launched, and the “Thousand Medical Alliance Membership Program” has been fully launched to build a new intelligent remote surgery network platform with real-time multi-point interconnection, fully demonstrating the exclusive remote technology advantages of low latency, high fidelity, strong guarantee, and cloud interconnection. Continuously leading remote surgery, setting a historical record Remote surgery breaks through the limitations of space on surgical procedures, allowing high-quality medical resources and advanced surgical techniques from central cities to be projected in real-time to remote areas. It has important significance in alleviating uneven distribution of medical resources and promoting the sharing of advanced surgical technologies. In recent years, Edge Medical® Jointly with the General Hospital of the ...
- Source: drugdu
- 93
- September 5, 2024
JCI | Zhu Yingjie’s team from Shenzhen Advanced Institute reveals a new central target of GLP-1R agonist, a “weight loss drug”

Obesity, as one of the top ten chronic diseases worldwide, has a research history of over a century in the field of weight loss drugs. After 2014, glucagon like peptide-1 (GLP-1) receptor agonists emerged as a new force, far surpassing other weight loss drugs in terms of efficacy and safety, and also driving the development and marketing of weight loss drugs. GLP-1, as an intestinal insulinotropic hormone, is generated by the post-translational cleavage of pre glucagon encoded by the pre glucagon gene (GCG). It is mainly secreted by intestinal L cells and a portion of neurons in the solitary tract nucleus (NTS) of the brainstem. The action of GLP-1 is mediated by the GLP-1 receptor (GLP-1 R) and is widely distributed in the peripheral and central nervous systems. Liraglutide is a short acting GLP-1 receptor agonist that acts on the central nervous system to reduce appetite and slow gastric emptying. ...
- Source: drugdu
- 93
- September 5, 2024
The Lancet reports that semaglutide has the potential to be used in heart failure patients

Recently, The Lancet published a new centralized, participant level analysis of heart failure patients with mild reduced ejection fraction or preserved ejection fraction (HFpEF) from four randomized placebo-controlled trials (2.4 mg for SELECT, STEP-HFpEF, STEP-HFpEF DM; 1.0 mg/d). picture According to analysis, semaglutide reduced the composite risk of cardiovascular (CV) death or worsening heart failure (HF) events by 31%, with incidence rates of 5.4% in the semaglutide group and 7.5% in the placebo group (HR 0.69; 95% CI 0.53-0.89; P=0.0045). semaglutide also reduced the risk of HF worsening by 41% (2.8% vs. placebo 4.7%; HR 0.59 (95% CI 0.41-0.82), p=0.0019). Simeglutide had no significant effect on the incidence of CV mortality (3.1% in the Simeglutide group and 3.7% in the placebo group). Hr 0.82 (95% CI 0.57-1.16), p=0.25) The statistical analysis did not adjust for multiplicity, and the hazard ratio should not be used to infer definitive treatment efficacy. In ...
- Source: drugdu
- 70
- September 5, 2024
semaglutide is gaining ground

As we enter 2024, the global competition for “King of Medicine” is becoming increasingly fierce. In the first half of the year, Merck’s PD-1 monoclonal antibody pembrolizumab (trade name: Keytruda, “Keytruda”) successfully won the title of the world’s “king of medicine” with $14 billion. Novo Nordisk’s semaglutide (including 3 brands: Ozempic/Rybelsus/Wegovy) ranked second with sales of about $13 billion in the first half of this year, further narrowing the gap with Keytruda, and the year-on-year growth rate exceeded 40%, leaving suspense for the “king of medicine” competition in the second half of the year. On the other hand, in terms of sales growth, Eli Lilly’s tirpotide (including two brands: Mounjaro/Zepbound) grew 330% year-on-year in the first half of this year to $6.658 billion, making it the fastest-growing drug in history. Since its first indication was approved in 2022, it has grown into a super blockbuster with annual sales of over ...
- Source: drugdu
- 63
- September 5, 2024
Focusing on complement, standardized diagnosis and treatment of rare diseases usher in a new chapter

So far, the 2024 medical insurance catalog adjustment has announced the drugs and related information that have passed the formal review. From the draft for comments, rare disease drugs are still one of the focuses of the medical insurance catalog adjustment. Rare diseases are also called “orphan diseases”. Most of them are congenital diseases, chronic diseases, and may be life-threatening. Although the incidence of rare diseases is low, there are many types of diseases and the number of patients cannot be underestimated. At present, there are more than 7,000 confirmed rare diseases in the world, and there are about 20 million rare disease patients in China1. For a long time, the clinical phenotypes of rare diseases and common diseases overlap greatly, and early diagnosis is difficult, so the misdiagnosis and missed diagnosis rates are high. According to statistics from the National Organization for Rare Diseases in the United States, among ...
- Source: drugdu
- 52
- September 5, 2024
The Low Point of Performance Due to Centralized Procurement Has Passed, and Tonghua Dongbao Ushered in a Stable Development Period

On the evening of August 30, Tonghua Dongbao (600867.SH) released its 2024 semi-annual report, during the report period, the company achieved operating income of about 740 million yuan, a year-on-year decrease of 45.84%; net profit attributable to shareholders of listed companies of about -230 million yuan; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses of about -0.13 billion yuan. Industry analysts believe that the reason why Tonghua Dongbao fell into a loss, stemming from the biggest cyclical factors – insulin special centralized procurement. Similar to the first centralized procurement, the results of this year’s renewal have not been reflected in the performance for the time being. The main reason for the company’s first-half performance fluctuations is a one-time dealer to make up the difference, which was also the case in the last centralized procurement, fell to a low point in the second quarter, the ...
- Source: drugdu
- 78
- September 5, 2024
Lancet reports that semaglutide has the potential to be used in heart failure patients

According to analysis, semaglutide reduced the composite risk of cardiovascular (CV) death or worsening heart failure (HF) events by 31%, with incidence rates of 5.4% in the semaglutide group and 7.5% in the placebo group (HR 0.69; 95% CI 0.53-0.89; P=0.0045). semaglutide also reduced the risk of HF worsening by 41% (2.8% vs. placebo 4.7%; HR 0.59 (95% CI 0.41-0.82), p=0.0019). Simeglutide had no significant effect on the incidence of CV mortality (3.1% in the Simeglutide group and 3.7% in the placebo group). Hr 0.82 (95% CI 0.57-1.16), p=0.25) The statistical analysis did not adjust for multiplicity, and the hazard ratio should not be used to infer definitive treatment efficacy. In the United States, semaglutide is not approved for use in heart failure. This study is a summary and post hoc participant level analysis of 3743 patients with a history of HFpEF from four randomized trials, aimed at examining the ...
- Source: drugdu
- 91
- September 4, 2024
AI imaging company Yinghe Yimai announces completion of angel round financing

Today (September 2nd), Shanghai Yinghe Yimai Intelligent Technology Co., Ltd. (hereinafter referred to as “Yinghe Yimai”) announced the completion of an angel round financing of tens of millions of yuan, led by CICC Capital, marking a solid step forward for Yinghe Yimai in promoting the intelligentization of medical imaging. Multiple core products, focusing on intelligent medical imaging Yinghe Medical Pulse was founded in 2020 and is a continuous innovator in the field of medical imaging artificial intelligence based on its newly developed MIIA base model. In response to the current situation where medical imaging AI products are generally single disease, fragmented, and homogeneous, and cannot meet the actual needs of image reading work, Yinghe Medical Pulse is an emerging technology enterprise focused on medical imaging AI integration and research and development. It is committed to providing medical imaging auxiliary tools based on AI and statistical methods, as well as medical ...
- Source: drugdu
- 74
- September 4, 2024
Will Novo Nordisk’s Wegovy follow up with the price reduction of over 50% for Eli Lilly’s Zepbound?

MU Biotech Circle Recently, Eli Lilly announced plans to directly sell single dose vials of its weight loss drug Zepbound (tirzepatide) to consumers. The new prices for 2.5mg and 5.0mg doses are $99.75/vial and $137.25/vial, respectively, with corresponding monthly costs of $399 and $549, respectively, with a price reduction of over 50%. Novo Nordisk may adopt a similar strategy towards its Wegovy, with specific details to be revealed by its CEO during a Senate Health Committee hearing on September 24th. Analysts have responded positively to Eli Lilly’s move to lower Zepbound prices and offer the drug through its new self funded pharmacy component on its direct to consumer platform LillyDirect (launched in January this year). Joon Lee, an analyst at Truist Securities, believes that given the high demand for patients willing to purchase at their own expense, there is no reason why other GLP-1 manufacturers should not adopt similar strategies. ...
- Source: drugdu
- 72
- September 4, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.